GSK (GSK) Q4 FY25 earnings call

GSK delivered strong Q4 FY25 results, driven by robust growth in Specialty Medicines and Vaccines, alongside solid cash generation. The company is focused on maximizing launch products, accelerating late-stage pipeline assets, and executing strategic business development to drive continued profitable growth in 2026 and beyond, while navigating expected headwinds in certain segments and currency.